AstraZeneca announces results from the SAFFRON Phase III trial of Tagrisso
AstraZeneca (AZN) reported positive Phase III trial results for Tagrisso plus savolitinib in EGFR-mutated NSCLC. The combination showed a 45% reduction in disease progression/death risk vs. chemotherapy, with median PFS of 7.6 months vs. 5.4 months. OS was extended by 4.9 months, with 70% of patients alive at one year vs. 53%. Results will be presented at ESMO Congress 2026.
How this was made
The 30-second read
Why it matters
The data represent a major efficacy improvement that could translate into a new revenue stream pending regulatory approval.
Market read
First disclosure of pivotal trial data for a potential blockbuster oncology drug, likely to move AZN and related biotech stocks.
What to watch
Competitive landscape with other EGFR inhibitors and potential pricing pressure.
Background
AstraZeneca (AZN) announced that its Tagrisso plus savolitinib combination achieved a 45% reduction in disease progression risk and a 32% reduction in death risk versus chemotherapy in a Phase III trial for EGFR‑mutated NSCLC.
Ticker impact
AstraZeneca reported positive Phase III SAFFRON trial results for Tagrisso plus savolitinib in EGFR‑mutated NSCLC, showing significant PFS and OS benefits.
upward pressure as market anticipates regulatory filing and commercial launch
Phase III data are material for a blockbuster oncology asset; historically such results trigger price gains.
Market effects
Strengthens the broader oncology/targeted therapy sector and may boost peer biotech stocks.
Positive bias for UK‑listed pharma and US biotech markets.
Global biotech investors will watch for FDA/EMA submissions following the trial.
Counterpoint
Regulatory hurdles or safety concerns could delay approval, limiting upside.
Key entities
- companyAstraZeneca
Pharmaceutical company reporting the trial results.
- drugTagrisso
AZN's EGFR inhibitor being tested in combination.
